Posted by Michael Wonder on 19 May 2023
Bausch + Lomb and Novaliq announce FDA approval of Miebo (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease
18 May 2023 - Miebo is the first and only prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from two consecutive pivotal Phase 3 trials.
Bausch + Lomb Corporation and Novaliq today announced that the US FDA has approved Miebo (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease.
